Login
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc.

ars-pharma.com

What Do They Do?

Sells neffy, a needle-free epinephrine nasal spray for emergency treatment of severe allergic reactions, to pharmaceutical wholesalers and pharmacy customers, for use by patients and healthcare providers.

How Do They Make Money?

U.S. customers buy neffy through wholesale distributors and pharmacies; the company is paid when products are delivered, or when a pharmacy sells a consigned product to a patient. Collaboration partners pay for licenses, milestones and royalties, and can also buy product supply.

revenue
SegmentShareRevenue
Product revenue, net
Sold outright

86%
Revenue under collaboration agreements
12%
Revenue under supply agreements
Sold outright

2.8%

Who Are Their Customers?

In the U.S., the company sells mainly to pharmaceutical wholesale distributors, with some sales to pharmacy customers; they resell to pharmacies and healthcare providers or dispense directly to patients. Outside the U.S., licensing and distribution partners commercialize neffy in their territories.

Do Revenues Turn Into Profits?

No. It lost $171.3M in FY2025.

Operating income, FY2025
−213% of revenue
▼ −5721% (Loss) vs FY2024 (−$3.1M, −3%)
Net income, FY2025
−203% of revenue
▼ Turned to a loss vs FY2024 ($8M, 9%)
Free cash flow, FY2025
−203% of revenue
▼ Turned to a loss vs FY2024 ($13M, 15%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +16%
vs $32.5M in Q3 FY2025
Net income
▲ +30% (Loss)
vs −$51.2M in Q3 FY2025
Product revenue, net share of revenue vs 96.3% in Q3 FY2025
  • Aug 13, 2026 ARS shifted commercial spending toward targeted prescriber outreach The company redirected resources from broad consumer advertising to high-volume prescribers and reduced spending; it also appointed Meg Smith as chief commercial officer.
  • Jul 7, 2026 Donn Casale replaced Richard Lowenthal as CEO

Growing. Revenue grew 15.3x in 4 years, from $5.5M in FY2021 to $84.3M in FY2025, about 98% a year.

From development to commercialization The older report described neffy as an investigational product candidate in clinical trials. The latest report describes neffy as an approved product that the company is commercializing, alongside ongoing development.

U.S. sales through wholesalers The latest report describes U.S. sales to pharmaceutical wholesale distributors and pharmacy customers, which then supply pharmacies, healthcare providers, or patients. The older report focused on developing neffy and prospective commercialization.

Revenue over time
Product revenue, net Revenue under collaboration agreements Revenue under supply agreements
$100M$50M$0

Who Do They Compete With?

Competes with Viatris, Teva Pharmaceuticals, Amneal Pharmaceuticals, Kaleo, Sandoz, Bryn Pharma, Hikma Pharmaceuticals, Nasus Pharma, Orexo, Insignis Therapeutics, Belhaven BioPharma, and Aquestive Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support